Bntx stocks.

The share price of BioNTech SE (BNTX) now. What analysts predict: $142.42. 52-week High/Low: $188.99 / $88. 50/200 Day Moving Average: $101.74 / $113.19. This figure corresponds to the Average Price over the previous 50/200 days. For BioNTech stocks, the 50-day moving average is the resistance level today.BioNTech SE American Depositary Share (BNTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Since initial coverage, BioNTech stock has lost $6 billion in value. BNTX's first quarter revenues were $5.6 billion less than 2022. People may be thinking the Covid-19 global pandemic is over.The stock of BioNTech SE ADR (BNTX) has gone down by -2.01% for the week, with a 3.63% rise in the past month and a -20.46% drop in the past quarter. The volatility ratio for the week is 3.45%, and the volatility levels for the past 30 days are 3.21% for BNTX. The simple moving […]

The share price of BioNTech SE (BNTX) now. What analysts predict: $142.42. 52-week High/Low: $188.99 / $88. 50/200 Day Moving Average: $101.74 / $113.19. This figure corresponds to the Average Price over the previous 50/200 days. For BioNTech stocks, the 50-day moving average is the resistance level today.BioNTech SE (NASDAQ:BNTX) posted its quarterly earnings results on Monday, November, 6th. The company reported $0.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $1.26. The firm had revenue of $895.30 million for the quarter, compared to analysts' expectations of $850.50 million.Nov 4, 2021 · Shares of BioNTech (BNTX-1.01%) were 9.1% lower as of 11:51 a.m. EDT on Thursday. The German biotech didn't report any news, so why did its stock slide? ... But stocks that share common ...

BioNTech ( NASDAQ: BNTX) has underperformed the broad market since my previous coverage, sporting a Seeking Alpha Quant D+ Momentum grad. The stock was downgraded to Hold after national and global ...

BioNTech stock (NASDAQ: BNTX), a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, declined by almost 31% over the last month, considerably underperforming the S&P 500 ...Are you tired of spending endless hours searching for high-quality stock photos only to discover that they come with a hefty price tag? Look no further. In this article, we will explore the best sources for high-quality really free stock ph...Headquartered in Mainz, Germany, BioNTech SE (NASDAQ:BNTX) is a biotechnology company. On July 3, 2023, BioNTech SE (NASDAQ:BNTX) stock closed at $107.82 per share. One-month return of BioNTech SE ...Real time BioNTech Se (BNTX) stock price quote, stock graph, news & analysis.

On November 14, 2022, BioNTech SE (NASDAQ:BNTX) stock closed at $160.37 per share. One-month return of BioNTech SE (NASDAQ:BNTX) was 15.42% and its shares lost 35.97% of their value over the last ...

Watching industrial stocks rise 500% above their bottom in 2009 was a real eye opener. After my master in molecular sciences, I did an MBA in management in 2010. During this studies I had courses ...

BioNTech (NASDAQ:BNTX – Get Free Report) was downgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating in a research note issued to investors on Friday, Marketbeat.com reports.They currently have a $99.00 target price on the stock, down from their previous target price of $106.00. JPMorgan …In Q3, BioNTech reported total revenues of €895.3m, all derived from COVID vaccine sales, a net profit of €161m, and diluted earnings per share ("EPS") of $0.67. Across the first nine months ...US09075V1026. BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2 ... The 16 analysts offering 1 year price forecasts for BNTX have a max estimate of — and a min estimate of —. Analyst rating Based on 18 analysts giving stock ratings to BNTX in the past 3 months.US09075V1026. BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2 ...

BioNTech SE BNTX shares declined 3.2% to $97.18 in pre-market trading. Now Read This: Dell Technologies, Genesco And 3 Stocks To Watch Heading Into Friday Don’t forget to check out our premarket ...3 Wall Street analysts have issued twelve-month price objectives for Better Therapeutics' stock. Their BTTX share price targets range from $3.00 to $9.00. On average, they predict the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 2,791.6% from the stock's current price.Get the latest BioNTech SE (BNTX) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.BNTX.O - | Stock Price & Latest News | Reuters SPX 4,550.58-0.09% IXIC 14,258.49 0.04% 0.32% BioNTech SE BNTX.O Latest Trade 99.25 USD 0 0.00% As of Nov 29, 2023. Values delayed up to 15...A high-level overview of BioNTech SE (BNTX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. BioNTech ( BNTX ): Despite recent losses, it’s seen as a cheap biotech stock with potential, trading at low free cash flow multiples and projecting healthy upside. Halozyme ( HALO ): Showed ...

A high-level overview of Moderna, Inc. (MRNA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.

21 Jun 2023 ... BNTX is more profitable, with a gross profit margin and net income margin of 85.29% and 51.08%, respectively, compared to MRNA's 39.82% and ...The analyst Jessica Fye also trims her price target on BNTX to $99 from $106 per share, arguing that the sinking estimations for the company's COVID-19 vaccine business have hurt the stock "and ...Holder Shares Date Reported % Out Value; Vanguard Horizon Fund-Capital Opportunity Fund: 2,234,636: Sep 29, 2023: 0.94%: 222,122,821: Primecap Odyssey Aggressive ...609.75M. -85.76%. Get the latest BioNTech SE - ADR (BNTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment ...3. BioNTech. Per its coronavirus vaccine collaboration with Pfizer, BioNTech ( BNTX 1.40%) is the only company on this list that's currently earning revenue as a result of its sales of mRNA ...20 Jan 2022 ... However, despite the strong financials, BioNTech stock trades at just 6x projected 2021 earnings. Although the low valuation multiple is partly ...View the latest BioNTech SE ADR (BNTX) stock price, news, historical charts, analyst ratings and financial information from WSJ. Cash Amount. Record Date. Pay Date. Jun 2, 2022. $2.111. Jun 3, 2022. Jun 17, 2022. * Dividend amounts are adjusted for stock splits when applicable. Get the latest dividend data for BioNTech SE (BNTX), including dividend history, yield, key dates, growth and other metrics.NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of BioNTech SE ("BioNTech" or the "Company") BNTX. Such investors are advised to contact ...

BNTX Stock Performance on November 6, 2023: Mixed Results and Concerns for Investors. BNTX stock performances on November 6, 2023 were mixed. The stock opened at $93.34, slightly higher than the previous day’s close of $92.49. Throughout the day, the stock’s price fluctuated within a range of $93.33 to $98.34.

See the latest CRISPR Therapeutics AG stock price (CRSP:XNAS), related news, ... BNTX Moderna Inc. MRNA Vertex Pharmaceuticals Inc. VRTX Valuation . View More. Metric CRSP BNTX

Find the latest Insider Activity data for BioNTech SE American Depositary Share (BNTX) at Nasdaq.com.Welcome to our investor page. Biopharmaceutical New Technologies, or BioNTech, is a global, fully integrated next-generation immunotherapy company pioneering novel therapies for cancer, infectious diseases and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of ...Oct 19, 2021 · BioNTech (NASDAQ: BNTX), a leader in messenger RNA technology and Pfizer’s Covid-19 vaccine partner, has seen its stock decline by almost 9.4% over the last week (five trading days) and by about ... BNTX Stock Performance on November 6, 2023: Mixed Results and Concerns for Investors. BNTX stock performances on November 6, 2023 were mixed. The stock opened at $93.34, slightly higher than the previous day’s close of $92.49. Throughout the day, the stock’s price fluctuated within a range of $93.33 to $98.34.Stocks with records like Novavax's are considered speculative. In the fourth quarter, NVAX stock analysts expect a per-share gain of 16 cents. On an adjusted basis, they expect a 60-cent loss.Shares of several COVID-19 vaccine makers were sliding on Monday. BioNTech stock ( BNTX 2.79%) was down 6.5% at 12:09 p.m. EDT. Shares of Moderna ( MRNA 5.54%) had slipped 4.4%. Novavax ( NVAX -0. ...BNTX Stock Performance on November 6, 2023: Mixed Results and Concerns for Investors. BNTX stock performances on November 6, 2023 were mixed. The stock opened at $93.34, slightly higher than the previous day’s close of $92.49. Throughout the day, the stock’s price fluctuated within a range of $93.33 to $98.34.Real-time Price Updates for Biontech Se ADR (BNTX-Q), along with buy or sell ... Why Pfizer and BioNTech Stocks Zoomed Higher Today. September 29, 2023. Motley ...Real time BioNTech Se (BNTX) stock price quote, stock graph, news & analysis.BNTX Stock: Mixed Performance and Challenges in Profitability and Growth. On November 6, 2023, BNTX stock showed mixed performance based on the available data. BNTX is a company in the Health Technology sector, specifically in the Biotechnology industry. With a market cap of $23.2 billion, BNTX is a significant player in the biotech field.3 days ago ... JPMorgan downgrades BioNTech (BNTX) due to uncertain outlook for COVID-19 vaccine, hurting company's shares in the pre-market.

Apr 20, 2023 · Nevertheless, contrarians might want to consider picking up BNTX. First, it sits among the blue-chip stocks with value based on key financial ratios. First, BNTX trades at a trailing multiple of 3 ... As investors are pricing in a Covid-19 vaccine from Pfizer, Inc. and BioNTech SE (), stocks in industries that were beaten down by the pandemic are witnessing some investor attention.However, high-flying tech companies have experienced downward pressure following the vaccine news, as the remote digital lifestyle is likely to take a back …BNTX Earnings Date and Information. BioNTech last posted its earnings data on November 6th, 2023. The reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $1.26. The firm had revenue of $895.30 million for the quarter, compared to analyst estimates of $850.50 million.Instagram:https://instagram. magellan midstream mergercorporate bonds for saleoptimus futures fees1979 liberty one dollar coin value See the latest Baidu Inc ADR stock price (BIDU:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Find the latest BioNTech SE (BNTX) stock quote, history, news and other vital information to help you with your stock trading and investing. blue cross blue shield dental reviewsosterweis strategic income As half of the duo behind one of the world's most widely used and effective COVID-19 vaccines, BioNTech (BNTX 1.37%) is well on its way to enduring stardom in the healthcare sector. Far from ... vox etf BioNTech ADRs drop after JPMorgan lowers outlook to "underweight". Investing.com -- U.S.-listed shares in BioNTech (NASDAQ:BNTX) dipped in early trading on Friday after analysts at JPMorgan ...BioNTech (NASDAQ:BNTX) is scheduled to announce Q2 earnings results on Monday, August 7th, before market open.The consensus EPS Estimate is -$0.82 and the consensus Revenue Estimate is $797.44M ...Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools. Identify stocks that meet your criteria using seven unique stock screeners.